- Deltex Medical Group
- 26 January 2022 10:31:07
Source: Sharecast
The order will also result in "attractive" ongoing contracted monthly revenues for the single-use probes which are used with these devices, Deltex said.
Over the past 18 months, the company and its distributor have been working in-market to gain regulatory approval for the current TrueVue monitor and to validate its use within the hospital systems. Initially the distributor purchased five monitors to carry out in-hospital evaluations and these trials proved successful, leading to the TrueVue technology being chosen to fulfil the initial government tender in that market.
As a result, Deltex has now received an initial order for monitors to fulfil government-awarded contracts, with installation expected over the next nine months. Further monitor orders are expected later this year once more tenders are awarded.
Deltex said that while direct sales in the UK and US markets have been hit significantly by Covid-19, it has re-focused its commercial activities on territories where it has been able to obtain regular access to operating rooms.
Chief executive officer Andy Mears said: "I am delighted by this contract award as it helps underscore the potential for growth and ongoing recurring probe revenues that exists for Deltex Medical's core TrueVue Doppler technology around the world."
Deltex makes and markets haemodynamic monitoring technologies which are primarily used in critical care and general surgical procedures. The company’s proprietary oesophageal Doppler monitoring (TrueVue Doppler) measures blood flow velocity in the central circulation in real time.